STOCK TITAN

AMGEN Inc. - AMGN STOCK NEWS

Welcome to our dedicated news page for AMGEN (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on AMGEN.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AMGEN's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AMGEN's position in the market.

Rhea-AI Summary
Amgen to present at Morgan Stanley Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
conferences
-
Rhea-AI Summary
Amgen and Horizon Therapeutics resolve pending FTC lawsuit, clearing the way for Amgen's acquisition of Horizon
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
-
Rhea-AI Summary
Amgen and Horizon Therapeutics resolve pending FTC lawsuit, clearing path for acquisition
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
Rhea-AI Summary
Amgen to present at Wells Fargo Healthcare Conference and Citi Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
conferences
-
Rhea-AI Summary
Amgen announces positive results from Phase 2 OCEAN(a)-DOSE study of olpasiran, showing a lasting effect on Lp(a) reduction nearly a year after the last dose. No new safety concerns identified. Amgen convenes LDL Awareness to Action Implementation Consortium to improve LDL-C testing and evidence-based treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Amgen's LUMAKRAS® (sotorasib) is set for review by the FDA Oncologic Drugs Advisory Committee for full approval in treating KRAS G12C-mutated NSCLC. LUMAKRAS has shown positive results in multiple studies and is approved in various markets. The comprehensive data package will be discussed at the meeting on Oct. 5, 2023. A PDUFA target action date of Dec. 24, 2023, has been set.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.18%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.45%
Tags
-
Rhea-AI Summary
Amgen declares a $2.13 per share dividend for the third quarter of 2023, payable on September 8, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
dividends
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
Rhea-AI Summary
Amgen receives full FDA approval for BLINCYTO® (blinatumomab) for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (B-ALL) in patients with minimal residual disease (MRD) at baseline after remission.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
none
AMGEN Inc.

Nasdaq:AMGN

AMGN Rankings

AMGN Stock Data

142.36B
534.35M
0.25%
80.73%
1.95%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Thousand Oaks

About AMGN

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the worlds largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.